1. Academic Validation
  2. Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication

Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication

  • J Med Chem. 2011 Dec 22;54(24):8670-80. doi: 10.1021/jm201264t.
Andrew V Stachulski 1 Chandrakala Pidathala Eleanor C Row Raman Sharma Neil G Berry Alexandre S Lawrenson Shelley L Moores Mazhar Iqbal Joanne Bentley Sarah A Allman Geoffrey Edwards Alison Helm Jennifer Hellier Brent E Korba J Edward Semple Jean-Francois Rossignol
Affiliations

Affiliation

  • 1 Robert Robinson Laboratories, Department of Chemistry, University of Liverpool, Liverpool L69 7ZD, UK. andrew.stachulski@bioch.ox.ac.uk
Abstract

We report the activities of a number of thiazolides [2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis C virus (HCV) genotypes IA and IB, using replicon assays. The structure-activity relationships (SARs) of thiazolides against HCV are less predictable than against hepatitis B virus (HBV), though an electron-withdrawing group at C(5') generally correlates with potency. Among the related salicyloylanilides, the m-fluorophenyl analogue was most promising; niclosamide and close analogues suffered from very low solubility and bioavailability. Nitazoxanide (NTZ) 1 has performed well in clinical trials against HCV. We show here that the 5'-Cl analogue 4 has closely comparable in vitro activity and a good cell safety index. By use of support vector analysis, a quantitative structure-activity relationship (QSAR) model was obtained, showing good predictive models for cell safety. We conclude by updating the mode of action of the thiazolides and explain the candidate selection that has led to compound 4 entering preclinical development.

Figures